FDA Clears Lilly’s Foundayo™ (orforglipron), the First GLP-1 Weight Loss Pill with No Food or Timing Restrictions
Eli Lilly and Company has announced a major milestone in the treatment of obesity with the approval of Foundayo (orforglipron) by the U.S. Food and Drug Administration. The newly approved therapy is indicated for adults living with obesity, as well as those who are overweight and have at least one weight-related medical condition. Designed as a once-daily oral medication, Foundayo represents a significant advancement in expanding treatment options for a condition that affects millions of individuals and remains under-treated globally.
The approval marks an important shift in the landscape of obesity care, particularly as it introduces a non-injectable option within the GLP-1–based therapeutic class. When used in combination with a reduced-calorie diet and increased physical activity, Foundayo has been shown to support both meaningful weight loss and long-term weight maintenance. Its oral formulation, which can be taken without food or water restrictions, offers a level of convenience that may help address some of the practical barriers associated with existing injectable therapies.
Lilly has outlined a rapid rollout plan for the medication. Foundayo will initially be available through LillyDirect, the company’s direct-to-patient platform, with prescriptions being accepted immediately and shipments beginning on April 6. Following this initial launch, the drug is expected to become widely available through U.S. retail pharmacies and telehealth providers, broadening access to patients across different care settings.
Obesity continues to present a significant public health challenge, often associated with serious comorbidities such as cardiovascular disease, type 2 diabetes, and hypertension. Despite the availability of effective treatments, a relatively small proportion of eligible patients currently receive pharmacological therapy. Experts attribute this gap to a combination of factors, including limited access, stigma, perceived complexity of treatment regimens, and under-recognition of obesity as a chronic disease requiring medical intervention.
Clinical experts have emphasized the importance of expanding treatment options that align with patient preferences and real-world needs. Deborah Horn, DO, director of the Center for Obesity Medicine at McGovern Medical School at UTHealth Houston, highlighted that many individuals may prefer an oral medication over injectable therapies. She noted that Foundayo’s flexibility—particularly the absence of dietary or hydration restrictions—can make it easier for patients to incorporate treatment into their daily routines.
The clinical efficacy of Foundayo is supported by data from the comprehensive ATTAIN clinical trial program. In the ATTAIN-1 study, participants receiving the highest dose of the medication experienced an average weight loss of 27.3 pounds, equivalent to 12.4% of body weight, among those who completed the trial. In comparison, individuals receiving placebo lost an average of 2.2 pounds, or 0.9% of body weight. When considering all participants regardless of trial completion, those treated with Foundayo achieved an average weight loss of 25 pounds (11.1%), compared to 5.3 pounds (2.1%) in the placebo group.
Beyond weight reduction, the ATTAIN program also demonstrated improvements in several key markers of cardiovascular risk. These included reductions in waist circumference, non-HDL cholesterol, triglyceride levels, and systolic blood pressure across all studied doses. Such findings suggest that Foundayo may offer broader metabolic benefits, addressing not only weight but also associated health risks that contribute to long-term morbidity and mortality.
David A. Ricks, Chair and Chief Executive Officer of Eli Lilly and Company, emphasized the broader implications of the approval. He noted that fewer than one in ten individuals who could benefit from GLP-1–based therapies are currently receiving them. According to Ricks, barriers such as access limitations, social stigma, and misconceptions about the seriousness of obesity have contributed to this gap. He expressed confidence that Foundayo, as a convenient oral therapy, could help make treatment more accessible and acceptable to a wider population.
Affordability and access are central to Lilly’s commercialization strategy for Foundayo. The company has introduced several pricing initiatives aimed at reducing out-of-pocket costs for patients. Eligible individuals with commercial insurance may be able to obtain the medication for as little as $25 per month through a savings program. For those without insurance coverage or who prefer to pay out of pocket, the starting price is set at $149 per month for the lowest dose. Additionally, Lilly has indicated that eligible Medicare Part D beneficiaries may have access to the drug at approximately $50 per month beginning July 1, 2026.
Patient advocacy groups have welcomed the introduction of additional treatment options in the obesity space. Joe Nadglowski, President and CEO of the Obesity Action Coalition, подчеркнул that there is no single solution that works for everyone living with overweight or obesity. He noted that expanding the range of available therapies allows individuals to choose options that best align with their personal preferences, treatment goals, and stage in their health journey. Whether patients are just beginning to explore medical treatment or seeking alternatives for long-term management, having more choices can improve engagement and outcomes.
As with all medications, Foundayo carries important safety considerations. The drug is not recommended for use in combination with other GLP-1 receptor agonists, and its safety and effectiveness in pediatric populations have not been established. A boxed warning highlights the potential risk of thyroid tumors, including thyroid cancer, observed in preclinical studies. Patients are advised to monitor for symptoms such as a lump or swelling in the neck, hoarseness, difficulty swallowing, or shortness of breath, and to report any such symptoms to their healthcare provider promptly.
Common side effects associated with Foundayo include gastrointestinal symptoms such as nausea, diarrhea, vomiting, constipation, indigestion, and abdominal pain. Additional reported effects include headache, fatigue, bloating, belching, heartburn, gas, and hair loss. While these side effects are generally manageable, patients and healthcare providers are encouraged to review the full prescribing information and medication guide to understand the complete safety profile.
Looking beyond the United States, Lilly is actively pursuing global expansion for orforglipron. The company has submitted regulatory applications for weight management and/or type 2 diabetes indications in more than 40 countries. Plans are in place to launch the therapy in international markets shortly after receiving the necessary approvals, reflecting the growing global demand for effective obesity treatments.
The approval of Foundayo underscores a broader evolution in obesity care, where innovative therapies are increasingly designed to meet the diverse needs of patients. By offering a convenient, effective, and potentially more accessible option, Lilly aims to address longstanding gaps in treatment uptake and improve health outcomes for individuals living with obesity and related conditions.
In conclusion, the introduction of Foundayo represents a meaningful advancement in the management of obesity, combining strong clinical efficacy with a user-friendly oral formulation. As healthcare systems continue to recognize obesity as a chronic and treatable disease, therapies like Foundayo may play a pivotal role in expanding access to care and supporting patients in achieving sustainable weight loss and improved overall health.
About Foundayo (orforglipron)4
Foundayo™ (orforglipron) is FDA-approved for adults with obesity, or some adults with overweight who also have weight-related medical problems to reduce excess body weight and maintain weight reduction long term, alongside a reduced-calorie diet and increased physical activity. Foundayo is a once-daily small molecule (non-peptide) oral glucagon-like peptide-1 receptor agonist that can be taken any time of the day without restrictions on food and water intake.5 Orforglipron was discovered by Chugai Pharmaceutical Co., Ltd. and licensed by Lilly in 2018. In addition to chronic weight management, orforglipron is being studied as a potential treatment for type 2 diabetes, obstructive sleep apnea, osteoarthritis knee pain, hypertension, peripheral artery disease and stress urinary incontinence.
About ATTAIN-1 and ATTAIN-2 clinical trial program
The ATTAIN Phase 3 global clinical development program for orforglipron has enrolled more than 4,500 people with obesity or overweight across two global registration trials.
ATTAIN-1 (NCT05869903) is a Phase 3, 72-week, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of orforglipron at various doses to placebo in adults with obesity, or overweight with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease, who did not have diabetes.
The trial randomized 3,127 participants across the U.S., Brazil, China, India, Japan, South Korea, Puerto Rico, Slovakia, Spain and Taiwan to receive various doses of orforglipron or placebo along with healthy diet and physical activity. The primary objective of the study was to demonstrate that orforglipron is superior to placebo in body weight reduction from baseline after 72 weeks.
ATTAIN-2 (NCT05872620) is a Phase 3, 72-week, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of various doses of orforglipron with placebo in adults with obesity or overweight and type 2 diabetes. The trial randomized over 1,600 participants across the U.S., Argentina, Australia, Brazil, China, Czechia, Germany, Greece, India, South Korea and Puerto Rico to receive various doses of orforglipron or placebo along with healthy diet and physical activity. The primary objective of the study was to demonstrate that orforglipron is superior to placebo in mean body weight change from baseline at 72 weeks.
Source Link:https://investor.lilly.com/
